tetano
Editor, Senior Moderator
Int J Med Sci. 2012;9(2):157-62. Epub 2012 Jan 13.
Inhaled nitric oxide therapy fails to improve outcome in experimental severe influenza.
Darwish I, Miller C, Kain KC, Liles WC.
Source
1. Institute of Medical Science, University of Toronto, Toronto, Canada;
Abstract
In vitro, nitric oxide (NO) has been shown to have antimicrobial activity against a wide range of viruses, including influenza A virus. Therefore, we hypothesized that inhaled nitric oxide (iNO) would increase survival in vivo by reducing the viral load in C57Bl/6 mice infected with a lethal dose of influenza A/WSN/33 (H1N1; WSN/33) virus. NO was delivered to influenza-infected mice either continuously or intermittently at 80 or 160 ppm, respectively, using both prophylactic and post-infection treatment strategies. Murine survival and weight loss were assessed, and lung viral load was quantified via plaque assay. Here, we report that iNO administered prophylactically or post-influenza infection failed to improve survival of infected mice. No difference in lung viral load was observed between experimental groups. Although NO has antiviral activity against influenza A virus in vitro, iNO therapy provided no apparent benefit when used for treatment of influenza A virus infection in vivo.
PMID:
22253563
[PubMed - in process]
PMCID: PMC3258558
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/22253563
Inhaled nitric oxide therapy fails to improve outcome in experimental severe influenza.
Darwish I, Miller C, Kain KC, Liles WC.
Source
1. Institute of Medical Science, University of Toronto, Toronto, Canada;
Abstract
In vitro, nitric oxide (NO) has been shown to have antimicrobial activity against a wide range of viruses, including influenza A virus. Therefore, we hypothesized that inhaled nitric oxide (iNO) would increase survival in vivo by reducing the viral load in C57Bl/6 mice infected with a lethal dose of influenza A/WSN/33 (H1N1; WSN/33) virus. NO was delivered to influenza-infected mice either continuously or intermittently at 80 or 160 ppm, respectively, using both prophylactic and post-infection treatment strategies. Murine survival and weight loss were assessed, and lung viral load was quantified via plaque assay. Here, we report that iNO administered prophylactically or post-influenza infection failed to improve survival of infected mice. No difference in lung viral load was observed between experimental groups. Although NO has antiviral activity against influenza A virus in vitro, iNO therapy provided no apparent benefit when used for treatment of influenza A virus infection in vivo.
PMID:
22253563
[PubMed - in process]
PMCID: PMC3258558
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/22253563